NYSE ARCA | ETF
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| NBIX | Neurocrine Biosciences Inc | Healthcare | Drug Manufacturers - Specialty & Generic | 4.91% |
| CERE | Cerevel Therapeutics Holdings Inc | Healthcare | Biotechnology | 4.9% |
| ITCI | Intracellular Th | Healthcare | Drug Manufacturers - Specialty & Generic | 4.86% |
| SRPT | Sarepta Therapeutics Inc | Healthcare | Biotechnology | 4.74% |
| AXNX | Axonics Modulation Technologies Inc | Healthcare | Medical Devices | 4.67% |
| ARGX | argenx NV ADR | Healthcare | Biotechnology | 4.49% |
| BIIB | Biogen Inc | Healthcare | Drug Manufacturers - General | 4.48% |
| KRTX | Karuna Therapeutics Inc | Healthcare | Biotechnology | 4.29% |
| PTCT | PTC Therapeutics Inc | Healthcare | Biotechnology | 4.24% |
| XENE | Xenon Pharmaceuticals Inc | Healthcare | Biotechnology | 4.1% |
| ALKS | Alkermes Plc | Healthcare | Drug Manufacturers - Specialty & Generic | 3.87% |
| IART | Integra LifeSciences Holdings | Healthcare | Medical Devices | 3.73% |
| BHVN | Biohaven Pharmaceutical Holding Co Ltd | Healthcare | Biotechnology | 3.73% |
| 326030 | Sk Biopharmaceuticals Co Ltd | Healthcare | Biotechnology | 3.53% |
| ACAD | ACADIA Pharmaceuticals Inc | Healthcare | Biotechnology | 3.3% |
| SUPN | Supernus Pharmaceuticals Inc | Healthcare | Drug Manufacturers - Specialty & Generic | 3.27% |
| AVDL | Avadel Pharmaceuticals PLC | Healthcare | Drug Manufacturers - Specialty & Generic | 3.12% |
| CPRX | Catalyst Pharmaceuticals Inc | Healthcare | Biotechnology | 3.09% |
| NEU | Neuren Pharmaceuticals Ltd | Healthcare | Biotechnology | 2.82% |
| HLUN-B | H Lundbeck A/S | Healthcare | Drug Manufacturers - Specialty & Generic | 2.63% |
The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index. It is non-diversified.